28th September 2010

Ranolazine (Latixa®▼) 500mg tablets for the treatment of stable angina pectoris

The New Therapies Subgroup discussed the above drug at a meeting on the 23rd September 2008 and the 28th September 2010. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG considered the use of Ranolazine (Latixa®▼) for the treatment of stable angina pectoris.

The group does not recommend the use of Ranolazine (Latixa®▼) for add on therapy in patients who are inadequately controlled or intolerant to first-line antianginal therapies.

The group noted the modest efficacy when compared to placebo and safety concerns regarding its potential to cause QT-prolongation and potential high cost when compared to standard therapy.

Ranolazine may have a role for specialist initiation in patients who are not suitable for surgical intervention.

Review date: September 2012

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.